Cell-free donor-derived DNA – an outstanding tool for early detection of graft injury after kidney transplantation
Written by Dan Hauzenberg
We are excited to announce that we will be attending the cfDNA2023 conference. The meeting promises to provide an excellent overview of the field as presented by key experts and give us the opportunity to discuss scientific and clinical topics with peers from the field. We look forward to learning from and contributing to the conversation at cfDNA2023.
“During early pregnancy, 3-6% of cell-free DNA in the plasma of pregnant women is of fetal origin.”
Dr. Agneta Wikman, M.D., Ph.D, Karolinska University Hospital, Stockholm, Sweden
Choosing and implementing the best screening method for non-invasive fetal-RHD testing. Learn from clinical experts about the shift in today’s screening method for non-invasive fetal-RHD testing. Dr Wikman is a professor and specialist in Transfusion Medicine and Laboratory Medicine.
Podcast | December 6, 2022
Collaborations and homebrew assays by Dan Hauzenberger & Turid Sundin CarlssonNews | November 10, 2022
Devyser Diagnostics AB publishes Interim Report for the period, January to September 2022News | November 9, 2022
Devyser strengthens its presence on the US market - establishes proprietary CLIA labWritten by Dan Hauzenberg
Read More
Swedish molecular diagnostics company Devyser, announced today at the 45th annual European Bone...
Read More
Chimerism monitoring after hematopoietic stem cell transplantation (HSCT) plays a key role in...
Read More
Devyser offers an online Sequence Coverage Calculator to help plan your NGS run for optimal...
Read More